Evidence map›Paper›PMID 41129601›Full record

ArticleCancer research communications2025

Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts.

J Jason Morton, Stephan A Ramos, Nathaniel Alzofon, Stephen B Keysar, Lucas H Armitage, Alexander S Baker, Jessie M Barra, Tugs-Saikhan Chimed, Phuong N Le, Cera Nieto and 8 more

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

J Jason Morton *Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-4171-8858
Stephan A Ramos *Charles C. Gates Center for Regenerative Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-7072-9735
Nathaniel Alzofon *Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0009-0006-8298-346X
Stephen B KeysarDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-5800-857X
Lucas H ArmitageCharles C. Gates Center for Regenerative Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0003-3179-4993
Alexander S BakerDiabetes Institute, University of Florida, Gainesville, Florida.ORCID 0009-0007-7296-7180
Jessie M BarraDiabetes Institute, University of Florida, Gainesville, Florida.ORCID 0000-0002-6456-9293
Tugs-Saikhan ChimedDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-8064-9165
Phuong N LeDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-7800-064X
Cera NietoDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-8835-6236
Alice N WeaverDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-9398-1471
Carissa M ThomasDepartment of Otolaryngology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0003-0765-5731
Bettina MillerDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-8825-6526
William RobinsonDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0003-1875-9691
Theresa M MedinaDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0009-0002-3799-4320
Dexiang GaoDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0003-3920-7060
Holger A RussCharles C. Gates Center for Regenerative Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-5117-2927
Antonio JimenoDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-8560-0440

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancerR01CA149456 · NCI · UNIVERSITY OF COLORADO DENVER · PI Antonio Jimeno · 2010 to 2026
$5.6M
Institutional Training in Otolaryngology ResearchT32DC012280 · NIDCD · UNIVERSITY OF COLORADO DENVER · PI Yuri Agrawal, Sue C. Kinnamon · 2013 to 2026
$3.4M
American Cancer Society (ACS) ACS-IRG 16-184-56Anschutz Medical Campus, University of Colorado (CU AMC)Children's Diabetes Foundation (CDF)Daniel and Janet Mordecai FoundationKarsh Family FoundationNational Cancer Institute (NCI) P30-CA046934National Cancer Institute (NCI) R01CA149456National Institute on Deafness and Other Communication Disorders (NIDCD) T32DC012280NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA149456NIDCD NIH HHS T32 DC012280Peter and Rhonda Grant FoundationU.S. Department of Defense (DOD) CA171179
6 · The paper itself

Abstract

A fundamental limitation of HLA-A matched humanized mice (mHM), generated with donor hematopoietic stem and progenitor cells and bearing patient-derived xenografts, is that the fidelity of the interaction between the immune system and implanted tumors is limited by lack of thymic T-cell education. We created a model with patient-matched thymic and tumor tissue by using patient peripheral blood mononuclear cells reprogrammed into induced pluripotent stem cells to generate stem cell-derived thymic organoids (sTOs). When implanted in thymectomized mHM, which were subsequently engrafted with patient melanoma tissue (autologous, or mHMTA), sTOs expressed thymic tissue markers EPCAM, KRT5, and KRT8 and contained developing double-positive T cells. mHMTA had more activated HLA-DR+ T cells in their spleens. Tumor growth in mHMTA was significantly slower compared with mHM, and both tumor volume and viable melanoma content were significantly decreased in mHMTA. This was associated with an increase of intratumoral activated T cells in mHMTA. Whole-exome sequencing followed by intratumoral heterogeneity analysis identified seven candidate neoantigens that were selected against in the mHMTA model, suggesting more effective identification and T cell-driven tumor clearance. This study shows the feasibility of generating patient-specific, thymus-bearing mice and provides a promising new tool in immunology and immunotherapy development. SIGNIFICANCE: A humanized mouse xenograft model, in which T cells are educated in a patient-derived implanted thymic organoid autologous to the tumor, provides a more faithful and complete environment to study cancer immunity.

Indexed as

MelanomaOrganoidsThymus GlandT-LymphocytesAnimalsAntigens, NeoplasmFemaleHumansInduced Pluripotent Stem CellsMiceXenograft Model Antitumor AssaysAntigens, Neoplasm

Identifiers

PMID41129601
PMCPMC12641387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.